Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01889407
Recruitment Status : Unknown
Verified July 2013 by Nanfang Hospital of Southern Medical University.
Recruitment status was:  Recruiting
First Posted : June 28, 2013
Last Update Posted : April 21, 2015
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Nanfang Hospital of Southern Medical University